Why the Latest IPO Wave Won’t Be Won on Science Alone.

IPO activity does more than unlock capital

In the last cycle, the path to public markets was faster and often built on future potential. This time, the bar is higher and far more defined. Companies are expected to show stronger data, clearer strategy, and a credible path to execution. As 2026’s biotech funding landscape unfolds, capital markets are once again opening doors for ambitious clinical-stage developers.

A concrete example of this is Generate:Biomedicines, which has filed for a Nasdaq IPO, aiming to raise up to $425 million. The company plans to use a large portion of the proceeds to advance its lead anti-TSLP antibody through a pair of Phase 3 severe asthma trials, potentially enrolling ~1,600 patients. Designed with AI-guided engineering and dosed only every six months, this long-acting antibody represents a novel push in respiratory biologics. Beyond its asthma programme, the IPO proceeds are also earmarked to support ongoing early-stage studies for additional candidates and to fuel broader platform innovation; a clear sign that investor appetite is returning to biotech equity markets after a quieter 2025.

That shift does not just affect the companies going public. It influences the entire ecosystem around them.

Private companies begin preparing earlier. Investors become more selective. Boards start thinking differently about risk and readiness.

In short, IPO activity raises the standard for everyone.

The ripple effect is underway!

As the IPO window begins to reopen, its impact is spreading well beyond the small group of companies planning to list. Decisions that were delayed are now being made. Growth plans are being revisited. Leadership teams are being evaluated not just for where the company is today, but for where it needs to be in two to three years.

The main reason for this is acknowledgement of the fact that once the market is moving, standing still becomes a risk and that is where the second-order effects begin to show.

Talent demand is moving earlier and intensifying

One of the clearest effects of this reemergence is in hiring.
As companies start preparing for IPO, they are pulling forward their talent strategies. Roles that might previously have been hired closer to a listing are now being filled much earlier. Leadership hiring is no longer reactive. It is becoming proactive and increasingly competitive.

There is a limited pool of individuals who have taken biotech companies through late-stage development and into the public markets. As more companies begin preparing at the same time;  as evidenced by filings like Generate:Biomedicines’ demand for that experience rises quickly.

The result is a quiet but important shift.
The competition for talent is no longer happening at IPO. It is happening well before it.

This creates a widening gap between companies
Not every company will move at the same pace. Those that recognise this shift early are already building the teams they need. They are strengthening leadership, adding experience, and positioning themselves for what comes next.

Others will wait for clearer market signals, but that gap in timing could be the biggest difference. By the time IPO activity becomes more visible, much of the most relevant talent will already be in place elsewhere. What looks like a funding window from the outside increasingly becomes a preparation race behind the scenes.

Over time, that creates a separation between companies that are ready to move and those that are still catching up.

What this means for talent and where this leads next? 

For experienced leaders, this environment creates opportunity.
Demand is increasing, but so is selectivity. Companies are not just hiring for capability; they are hiring for credibility. The right individuals do not just build businesses; they influence investor confidence.

For the next generation of leaders, expectations will shift.
It is no longer enough to be strong in one area. The market values people who can operate across functions, understand commercial realities, and contribute to scaling a business, not just advancing the science.

As IPO activity increases, talent becomes more concentrated in the companies that are best prepared and that concentration compounds over time.

If momentum continues in this fashion, a few patterns could emerge:

 • More companies will begin positioning for IPO earlier in their lifecycle.
 • Preparation timelines will extend around leadership and organisational build.
 • The number of IPOs may increase, but the gap in quality between them will become more pronounced.
 • Competition for talent will intensify before the competition for capital becomes visible.

The return of IPOs is only the starting point

So how do we make sense of the situation at hand?
The return of biotech IPOs is more than a headline; it is a signal of a market that now rewards preparation, execution, and leadership as much as science. The real-world filing of Generate: Biomedicines underlines this: investors are actively supporting companies that combine clinical innovation with a credible roadmap to public markets.

In this environment, the window is open but selective. Companies that anticipate the market, build strong teams, and align execution with vision will shape the next chapter of biotech. Those who wait risk being outpaced by the organisations and people who are ready.

Ultimately, IPOs may grab the headlines, but it is talent that writes the story.
If securing the right leadership and building teams capable of executing at this level feels daunting, now is the time to act.

Get in touch to see how Barrington James can help your team navigate this IPO window with the right leadership and talent in place.
https://www.barringtonjames.com/contact-us/